Compounds > 2-methylene-19-nor-(20s)-1alpha-25-dihydroxyvitamin-d3

2-methylene-19-nor-(20s)-1alpha-25-dihydroxyvitamin-d3 and Bone-Diseases--Metabolic

2-methylene-19-nor-(20s)-1alpha-25-dihydroxyvitamin-d3 has been researched along with Bone-Diseases--Metabolic* in 1 studies

Trials

1 trial(s) available for 2-methylene-19-nor-(20s)-1alpha-25-dihydroxyvitamin-d3 and Bone-Diseases--Metabolic

Article	Year
The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: results of a 1-year phase 2 double-blind, placebo-controlled, randomized clinical trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2011, Volume: 26, Issue:3 Most osteoporosis drugs act by inhibiting bone resorption. A need exists for osteoporosis therapies that stimulate new bone formation. 2-Methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2MD) is a vitamin D analogue that potently stimulates bone formation activity in vitro and in the ovariectomized rat model. In this randomized, double-blind, placebo-controlled study of osteopenic women, the effect of daily oral treatment with 2MD on bone mineral density (BMD), serum markers of bone turnover, and safety were assessed over 1 year. Volunteers were randomly assigned to three treatment groups: placebo (n = 50), 220 ng of 2MD (n = 54), and 440 ng of 2MD (n = 53). In general, 2MD was well tolerated. Although 2MD caused a marked increase in markers of bone formation, it did not significantly increase BMD. Since 2MD also shows marked activity on bone resorption (as revealed by dose-dependent increases in serum C-telopeptide cross-links of type I collagen in this study), 2MD likely stimulated both bone formation and bone resorption, thereby increasing bone remodeling. Topics: Animals; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Calcitriol; Calcium; Demography; Double-Blind Method; Female; Humans; Middle Aged; Parathyroid Hormone; Placebos; Postmenopause; Rats; Vitamin D	2011

Article

Year

The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: results of a 1-year phase 2 double-blind, placebo-controlled, randomized clinical trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2011, Volume: 26, Issue:3

Most osteoporosis drugs act by inhibiting bone resorption. A need exists for osteoporosis therapies that stimulate new bone formation. 2-Methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2MD) is a vitamin D analogue that potently stimulates bone formation activity in vitro and in the ovariectomized rat model. In this randomized, double-blind, placebo-controlled study of osteopenic women, the effect of daily oral treatment with 2MD on bone mineral density (BMD), serum markers of bone turnover, and safety were assessed over 1 year. Volunteers were randomly assigned to three treatment groups: placebo (n = 50), 220 ng of 2MD (n = 54), and 440 ng of 2MD (n = 53). In general, 2MD was well tolerated. Although 2MD caused a marked increase in markers of bone formation, it did not significantly increase BMD. Since 2MD also shows marked activity on bone resorption (as revealed by dose-dependent increases in serum C-telopeptide cross-links of type I collagen in this study), 2MD likely stimulated both bone formation and bone resorption, thereby increasing bone remodeling.

Topics: Animals; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Calcitriol; Calcium; Demography; Double-Blind Method; Female; Humans; Middle Aged; Parathyroid Hormone; Placebos; Postmenopause; Rats; Vitamin D

2011